This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2011 Mar;12(3):163-4.

doi: 10.1097/CND.0b013e3181df2b3e.

Rituximab in the treatment of MuSK antibody-positive myasthenia gravis

Beth Stein, Shawn J Bird

PMID: 21321497
DOI: 10.1097/CND.0b013e3181df2b3e

Case Reports

Rituximab in the treatment of MuSK antibody-positive myasthenia gravis

Beth Stein et al. J Clin Neuromuscul Dis. 2011 Mar.

. 2011 Mar;12(3):163-4.

doi: 10.1097/CND.0b013e3181df2b3e.

Authors

Beth Stein, Shawn J Bird

PMID: 21321497
DOI: 10.1097/CND.0b013e3181df2b3e

No abstract available

PubMed Disclaimer

Comment on

Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
Nelson RP Jr, Pascuzzi RM, Kessler K, Walsh LE, Faught PP, Ramanuja S, Pescovitz MD, Loehrer PJ Sr. Nelson RP Jr, et al. J Clin Neuromuscul Dis. 2009 Jun;10(4):170-7. doi: 10.1097/CND.0b013e31819a8403. J Clin Neuromuscul Dis. 2009. PMID: 19494727 Review.

Similar articles

Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
Kuntzer T, Carota A, Novy J, Cavassini M, Du Pasquier RA. Kuntzer T, et al. Neurology. 2011 Feb 22;76(8):757-8. doi: 10.1212/WNL.0b013e31820d6290. Neurology. 2011. PMID: 21339503 No abstract available.
Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
Keung B, Robeson KR, DiCapua DB, Rosen JB, O'Connor KC, Goldstein JM, Nowak RJ. Keung B, et al. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1407-9. doi: 10.1136/jnnp-2012-303664. Epub 2013 Jun 12. J Neurol Neurosurg Psychiatry. 2013. PMID: 23761915 No abstract available.
Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E. Illa I, et al. J Neuroimmunol. 2008 Sep 15;201-202:90-4. doi: 10.1016/j.jneuroim.2008.04.039. Epub 2008 Jul 23. J Neuroimmunol. 2008. PMID: 18653247
[Myasthenia gravis induced by autoantibodies against MuSK].
Shigemoto K, Konishi T, Ohta M. Shigemoto K, et al. Nihon Rinsho. 2008 Jun;66(6):1149-54. Nihon Rinsho. 2008. PMID: 18540361 Review. Japanese.
Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L. Rivner MH, et al. Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004. Neurol Clin. 2018. PMID: 29655451 Free PMC article. Review.

See all similar articles

Cited by

A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience.
Ziaadini B, Karimi N, Panahi A, Okhovat AA, Fatehi F, Nafissi S. Ziaadini B, et al. Curr J Neurol. 2022 Apr 4;21(2):91-97. doi: 10.18502/cjn.v21i2.10492. Curr J Neurol. 2022. PMID: 38011443 Free PMC article.
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.
Cao Y, Lu X, Wang J, Zhang H, Liu Z, Xu S, Wang T, Ning S, Xiao B, Wang L. Cao Y, et al. Int J Mol Med. 2017 Feb;39(2):268-278. doi: 10.3892/ijmm.2017.2853. Epub 2017 Jan 11. Int J Mol Med. 2017. PMID: 28075449 Free PMC article.
Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.
Stathopoulos P, Kumar A, Heiden JAV, Pascual-Goñi E, Nowak RJ, O'Connor KC. Stathopoulos P, et al. Ann N Y Acad Sci. 2018 Jan;1412(1):154-165. doi: 10.1111/nyas.13535. Ann N Y Acad Sci. 2018. PMID: 29381221 Free PMC article. Review.
Myasthenia gravis: an update for the clinician.
Sieb JP. Sieb JP. Clin Exp Immunol. 2014 Mar;175(3):408-18. doi: 10.1111/cei.12217. Clin Exp Immunol. 2014. PMID: 24117026 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Medical
- MedlinePlus Health Information